Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

ARS Pharmaceuticals (SPRY) Receivables - Other (2021 - 2025)

ARS Pharmaceuticals' Receivables - Other history spans 5 years, with the latest figure at $1.3 million for Q3 2025.

  • For Q3 2025, Receivables - Other rose 913.53% year-over-year to $1.3 million; the TTM value through Sep 2025 reached $1.3 million, up 913.53%, while the annual FY2024 figure was $1.2 million, 592.13% up from the prior year.
  • Receivables - Other for Q3 2025 was $1.3 million at ARS Pharmaceuticals, up from $1.1 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $1.3 million in Q3 2025 and bottomed at $16000.0 in Q4 2022.
  • The 5-year median for Receivables - Other is $208000.0 (2023), against an average of $454307.7.
  • The largest annual shift saw Receivables - Other crashed 89.94% in 2022 before it surged 1012.5% in 2023.
  • A 5-year view of Receivables - Other shows it stood at $159000.0 in 2021, then plummeted by 89.94% to $16000.0 in 2022, then soared by 1012.5% to $178000.0 in 2023, then soared by 592.13% to $1.2 million in 2024, then grew by 9.42% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Receivables - Other are $1.3 million (Q3 2025), $1.1 million (Q2 2025), and $710000.0 (Q1 2025).